View Older Stories View More Recent Stories
-
Roth Comments on Regeneron's (REGN) MAA Submission for EYLEA to EU; Reaffirms 'Buy' Rating
-
Roth Positive on TG Therapeutics (TGTX) into EHA Presentation
-
Roth Affirms 'Buy' Rating on MEI Pharma (MEIP); New AML Treatment Data Bolsters Confidence
-
Roth Halves PT on Dendreon (DNDN) to 50c; Things Aren't Shaping Up Nicely
-
Roth Keeps Pharmacyclics (PCYC) at 'Buy'; Imbruvica sNDA Selected for Priority Review by FDA
-
Roth Capital Starts MacroGenics (MGNX) at Buy
-
Marrone Bio Innovations Announces Pricing of Follow-on Offering
-
Hudson Technologies, Inc. (HDSN) Plans Common Stock Offering
-
Culture Still Intact at Curis (CRIS) Following Management Shift; Roth Affirms at 'Buy'
-
LeMaitre Vascular, Inc. Closes Public Offering of Common Shares
-
Roth Comments on DoC Prelim. Countervailing Duties (SCTY) (SPWR) (FSLR) (YGE)
-
Pharmacyclics (PCYC) KOL Event at ASCO Impresses Physicians; Roth Keeps at 'Buy'
-
ORR in Sunesis Pharma's (SNSS) Vosaroxin + Decitabine Phase III Improves; Roth Affirms 'Buy' Rating
-
Synta (SNTA) Management Ready to Take Company to Next Level; Roth Affirms 'Buy' Rating
-
Roth Keeps Celldex (CLDX) at 'Focus Pick'; Strong Phase I Data for Varlilumab Only Adds to Story
-
Cytokinetics (CYTK) BENEFIT-ALS Update 'Encouraging'; Roth Maintains 'Buy' Rating
-
Roth Still Positive on Galena Biopharma (GALE) Following GALE-301 FBP Presentation; Issues Commentary
-
Roth Keeps Pharmacyclics (PCYC) at Buy; Still Positive on Imbruvica Following Phase III RESONTAE
-
UPDATE: Roth Capital Upgrades ImmunoCellular Therapeutics (IMUC) to Buy
-
Roth Keeps TG Therapeutics (TGTX) as 'Focus Pick' Following ASCO Presentations
-
Notable Analyst Rating Changes 05/30: (MFRM) (OVTI) (AVY) Upgraded; (SOL) (BLOX) (EXAS) Downgraded
-
Roth Cuts ReneSola (SOL) to Neutral; DG Straegy, OEM Model are Both Negatives
-
Roth Capital Downgrades ReneSola Ltd. (SOL) to Neutral
-
Roth Positive on Retrophin's (RTRX) Thiola Licensing Deal; Issues Commentary
-
Another Partnership in the Books, Focus Now on ASCO for Celldex (CLDX) - Roth
-
Roth Affirms 'Buy' Rating on JinkoSolar (JKS); FY14 Project Outlook 'Encouraging'
-
Superior Drilling Products (SDPI) IPO Opens Flat
-
Superior Drilling Products (SDPI) IPO prices at $4, Below Expected Range
-
Roth 'Encouraged' by Ligand/Viking Transaction; Maintains at 'Buy' (LGND)
-
Roth Keeps Keryx Biopharma (KERX) at 'Buy' on PDUFA Update; Extension Preferred to CRL
-
Trina Solar (TSL) On-Track to Reach Capacity Targets, but Poly Pricing Risk Remains
-
Notable Analyst Rating Changes 05/22: (FB) (BAH) (NBR) Upgraded; (MT) (AEO) (SODA) Downgraded
-
Pre-Open Stock Movers 5/22: (NTLS) (ROYL) (PLCE) (SN) Higher; (WUBA) (WB) (MOV) (SINA) Lower (more...)
-
Roth Capital Adds TG Therapeutics (TGTX) to Focus List; Sees 2014 as 'Transformational'
-
Roth Capital Starts Sarepta Therapeutic (SRPT) at Buy
-
Roth Capital Downgrades Keurig Green Mountain (GMCR) to Neutral
-
Roth Trims PT, Ests on Canadian Solar (CSIQ); Execution in Canada, Japan Now Key
-
Hydrogenics Corp. (HYGS) Closes 1.5M Share Offering Priced at $15/sh
-
Roth Capital Keeps Stemline (STML) at 'Buy'; Still Plenty to See and Do in 2014
-
Roth Capital Starts Top Image Systems (TISA) at Buy
-
Sphere 3D to Acquire Overland Storage (OVRL) in All-Stock Deal
-
Roth Capital Starts Magellan Petroleum (MPET) at Buy
-
Roth Slashes PT on Plug Power (PLUG) to $3.75; Amid Positive Outlook, Several Areas Still Need Addressing
-
Roth Affirms Rexahn (RNN) at 'Buy'; Things Shaping Up for Solid Second-Half 2014
-
Roth Boosts PT on Coronado (CNDO) to $1.70; Sidelined Until TSO, CNDO-109 Trajectory Clears Up
-
Roth Capital Upgrades Summer Infant (SUMR) to Buy
-
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy'; Still Encouraged by Streamlining Efforts
-
Roth Trims PT on Orion Energy Systems (OESX) to $6; LED Hiccup Doesn't Disrupt Story
-
Roth Capital Upgrades Neogenomics (NEO) to Buy
-
Roth Reiterates 'Sell' Rating, $1 PT on Dendreon (DNDN) Following Q1 Report; Totality of Risks Remain High

